Aging—once deemed an irreversible march towards the increased risk of disorders and inevitable decline—now stands on the brink of a remarkable transformation. What seemed inevitable was upended in 2007 by Dr. Yamanaka’s Nobel Prize-winning breakthrough, revealing that introducing four specific genes—aptly named the Yamanaka factors (Oct4, Sox2, Klf4, c-Myc)—could reset the biological age of human and animal cells back to an embryonic state. It’s an insight that has deepened our understanding of aging on a cellular level and also led to the commercial cloning of adult animals, illuminating possibilities once consigned to science fiction.

Building upon this ground-breaking science, researchers have dialed back age-related changes in mice, charting a course towards the rejuvenation of cells. However, translating these findings to human therapies has been challenging, weighed down by potential side effects and significant costs.

Centagen is at the forefront of this revolution. We have recently filed patents for state-of-the-art nanotechnologies designed to circumvent the hurdles linked with the Yamanaka factors. Our therapeutic innovations are charting a path to reversing biological age by decades, offering a new horizon for combating the signs and symptoms associated with aging. If our therapies are verified and show effectiveness in clinical trials, we could be looking at a future where life for people in their 90’s and beyond is not significantly different than in their 20’s.

We stand on the cusp of a medical renaissance, where the dream of reversing aging is evolving from a bold vision into a tangible reality. We invite thought leaders, collaborators, and investors to embark with us on this exhilarating odyssey to redefine human longevity and unlock a future where healthy, vibrant biological youth at any age is the norm.